Literature DB >> 21685024

Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy.

Daniel C Cattran1, Heather N Reich, S Joseph Kim, Stéphan Troyanov.   

Abstract

BACKGROUND AND OBJECTIVES: The long-term effect of immunosuppressive therapy (IS) on kidney survival in idiopathic membranous nephropathy (MGN) is debated. The introduction of renin angiotensin blockade, rigorous BP control, and the increasing age at presentation of patients with MGN adds further uncertainty. Given these important changes, we sought to determine whether implementation of IS has altered outcome. DESIGN, SETTING, PARTICIPANTS, &
METHODS: We prospectively evaluated 280 incident MGN patients from three distinct 10-year periods starting from 1975.
RESULTS: We found expected changes in treatment regimens but also variations in age, renal function, severity of proteinuria, and BP at presentation over this time. Outcomes did not differ over time if these significant variations in clinical characteristics were not accounted for across the eras. The effect of IS in the 57 patients treated with currently recommended regimens was assessed using propensity adjustment to address selection bias and the effect of newer, conservative therapies. A propensity score estimating the probability of receiving IS permitted the pairing of 39 treated patients with controls with similar high risk of progression of clinical features. Using this approach, IS was associated not only with remissions in proteinuria but also with substantially improved renal survival.
CONCLUSIONS: The study confirms that patient presenting characteristics and management regimens have changed significantly over time and the natural history of MGN has been altered. A study of propensity-matched patients confirms that current recommendations for IS have improved outcomes in MGN patients at high risk of progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685024     DOI: 10.2215/CJN.11001210

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  9 in total

1.  Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.

Authors:  Jan A J G van den Brand; Peter R van Dijk; Julia M Hofstra; Jack F M Wetzels
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.

Authors:  Jan A J G van den Brand; Peter R van Dijk; Julia M Hofstra; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 8.237

Review 3.  Pathogenesis of membranous nephropathy: recent advances and future challenges.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Nat Rev Nephrol       Date:  2012-02-28       Impact factor: 28.314

4.  Rituximab in idiopathic membranous nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Antonietta Chianca; Annalisa Perna; Barbara Ruggiero; Flavio Gaspari; Alessandro Rambaldi; Maddalena Marasà; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

Review 5.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

6.  Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function.

Authors:  Yizhi Chen; Li Tang; Zhe Feng; Xueying Cao; Xuefeng Sun; Moyan Liu; Shuwen Liu; Xueguang Zhang; Ping Li; Ribao Wei; Qiang Qiu; Guangyan Cai; Xiangmei Chen
Journal:  J Nephrol       Date:  2014-02-13       Impact factor: 3.902

Review 7.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

8.  The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists.

Authors:  Sean Barbour; Monica Beaulieu; Jagbir Gill; Gabriela Espino-Hernandez; Heather N Reich; Adeera Levin
Journal:  Clin Kidney J       Date:  2014-10-24

9.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.

Authors:  Andrew Howman; Tracey L Chapman; Maria M Langdon; Caroline Ferguson; Dwomoa Adu; John Feehally; Gillian J Gaskin; David R W Jayne; Donal O'Donoghue; Michael Boulton-Jones; Peter W Mathieson
Journal:  Lancet       Date:  2013-01-09       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.